{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:19:51Z","timestamp":1794201591749,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15681-7","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:12:33Z","timestamp":1756743153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effect of tolvaptan on renal progression and systemic inflammation in ADPKD"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-8709","authenticated-orcid":false,"given":"Ahmet Ziya","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"4","key":"15681_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.molmed.2023.01.005","volume":"29","author":"L Luo","year":"2023","unstructured":"Luo, L., Roy, S., Li, L. & Ma, M. Polycystic kidney disease: novel insights into polycystin function. Trends Mol. Med. 29(4), 268\u2013281 (2023).","journal-title":"Trends Mol. Med."},{"issue":"5","key":"15681_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.5761\/atcs.oa.20-00364","volume":"27","author":"Y Futamura","year":"2021","unstructured":"Futamura, Y., Watanuki, H., Okada, M., Sugiyama, K. & Matsuyama, K. The efficacy and renal protective effect of tolvaptan in chronic kidney disease patients after open-heart surgery. Ann. Thorac. Cardiovasc. Surg. 27(5), 317\u2013321 (2021).","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"issue":"3","key":"15681_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11255-022-03353-8","volume":"55","author":"J Lu","year":"2023","unstructured":"Lu, J. et al. Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis. Int. Urol. Nephrol. 55(3), 631\u2013640 (2023).","journal-title":"Int. Urol. Nephrol."},{"key":"15681_CR4","unstructured":"FDA. Drug Approval Package: Jynarque (Tolvaptan). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/204441Orig1s000TOC.cfm (2021)."},{"issue":"25","key":"15681_CR5","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367(25), 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"15681_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2017","unstructured":"Torres, V. E. et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol. Dial. Transplant. 33(3), 477\u2013489 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"20","key":"15681_CR7","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377(20), 1930\u20131942 (2017).","journal-title":"N. Engl. J. Med."},{"key":"15681_CR8","first-page":"048","volume":"1","author":"P Geertsema","year":"2025","unstructured":"Geertsema, P. et al. The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD. Nephrol. Dial. Transplant. 1, 048 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"15681_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2215\/CJN.05850518","volume":"13","author":"KL Nowak","year":"2018","unstructured":"Nowak, K. L. et al. Vascular dysfunction, oxidative stress, and inflammation in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 13, 1493\u20131501. https:\/\/doi.org\/10.2215\/CJN.05850518 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"15681_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.semnephrol.2019.10.009","volume":"39","author":"M Theodorakopoulou","year":"2019","unstructured":"Theodorakopoulou, M., Raptis, V., Loutradis, C. & Sarafidis, P. Hypoxia and endothelial dysfunction in autosomal-dominant polycystic kidney disease. Semin. Nephrol. 39, 599\u2013612. https:\/\/doi.org\/10.1016\/j.semnephrol.2019.10.009 (2019).","journal-title":"Semin. Nephrol."},{"key":"15681_CR11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/antiox10071041","volume":"10","author":"V Ravarotto","year":"2021","unstructured":"Ravarotto, V., Bertoldi, G., Innico, G., Gobbi, L. & Cal\u00f2, L. The pivotal role of oxidative stress in the pathophysiology of cardiovascular-renal remodeling in kidney disease. Antioxidants. 10, 1041. https:\/\/doi.org\/10.3390\/antiox10071041 (2021).","journal-title":"Antioxidants."},{"key":"15681_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.315127.118","volume":"32","author":"J Cai","year":"2018","unstructured":"Cai, J. et al. A RhoA\u2013YAP\u2013c-Myc signaling axis promotes the development of polycystic kidney disease. Genes Dev. 32, 781\u2013793. https:\/\/doi.org\/10.1101\/gad.315127.118 (2018).","journal-title":"Genes Dev."},{"key":"15681_CR13","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/jcm9051328","volume":"9","author":"TM Seccia","year":"2020","unstructured":"Seccia, T. M., Rigato, M., Ravarotto, V. & Cal\u00f2, L. A. Rock (RhoA\/Rho kinase) in cardiovascular\u2013renal pathophysiology: a review of new advancements. J. Clin. Med. 9, 1328. https:\/\/doi.org\/10.3390\/jcm9051328 (2020).","journal-title":"J. Clin. Med."},{"issue":"7","key":"15681_CR14","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.ekir.2021.04.023","volume":"6","author":"P Stenvinkel","year":"2021","unstructured":"Stenvinkel, P. et al. Chronic inflammation in chronic kidney disease progression: role of Nrf2. Kidney International Reports. 6(7), 1775\u20131787 (2021).","journal-title":"Kidney International Reports."},{"issue":"3","key":"15681_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/ijms26031121","volume":"26","author":"T Lap\u00e3o","year":"2025","unstructured":"Lap\u00e3o, T., Barata, R., Jorge, C., Flores, C. & Calado, J. Autosomal dominant polycystic kidney disease inflammation biomarkers in the tolvaptan era. Int. J. Mol. Sci. 26(3), 1121 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"15681_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.106973","volume":"144","author":"T-C Wu","year":"2022","unstructured":"Wu, T.-C., Chang, W.-H., Lu, H.-Y. & Shih, C.-C. Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection. Vascul. Pharmacol. 144, 106973 (2022).","journal-title":"Vascul. Pharmacol."},{"issue":"5","key":"15681_CR17","doi-asserted-by":"publisher","first-page":"e00659","DOI":"10.1002\/prp2.659","volume":"8","author":"M El-Shabrawy","year":"2020","unstructured":"El-Shabrawy, M. et al. Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models. Pharmacol. Res. Perspect. 8(5), e00659 (2020).","journal-title":"Pharmacol. Res. Perspect."},{"issue":"4","key":"15681_CR18","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3390\/ijms25042088","volume":"25","author":"M Yamazaki","year":"2024","unstructured":"Yamazaki, M. et al. Long-term effects of tolvaptan in autosomal dominant polycystic kidney disease: predictors of treatment response and safety over 6 years of continuous therapy. Int. J. Mol. Sci. 25(4), 2088 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"8901","key":"15681_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","volume":"343","author":"D Ravine","year":"1994","unstructured":"Ravine, D. et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. The Lancet. 343(8901), 824\u2013827 (1994).","journal-title":"The Lancet."},{"issue":"3","key":"15681_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman, A. B. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7(3), 479\u2013486 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"15681_CR21","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1172\/JCI45161","volume":"121","author":"JV Bonventre","year":"2011","unstructured":"Bonventre, J. V. & Yang, L. Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 121(11), 4210\u20134221 (2011).","journal-title":"J. Clin. Invest."},{"issue":"9","key":"15681_CR22","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/ndt\/gfab193","volume":"36","author":"AL Messchendorp","year":"2021","unstructured":"Messchendorp, A. L. et al. Monocyte chemoattractant protein-1 and disease progression in ADPKD: a prospective cohort study. Nephrol. Dial. Transplant. 36(9), 1704\u20131712 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"15681_CR23","first-page":"1","volume":"45","author":"I Kocyigit","year":"2023","unstructured":"Kocyigit, I. et al. Serum interleukin-6 and TNF-\u03b1 levels in relation to total kidney volume and eGFR in patients with ADPKD. Renal Fail. 45(1), 1\u20138 (2023).","journal-title":"Renal Fail."},{"issue":"6","key":"15681_CR24","first-page":"969","volume":"32","author":"JJ Grantham","year":"2017","unstructured":"Grantham, J. J. et al. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol. Dial. Transplant. 32(6), 969\u2013975 (2017).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"15681_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1159\/000502999","volume":"50","author":"AL Messchendorp","year":"2019","unstructured":"Messchendorp, A. L. et al. Rapid progression of autosomal dominant polycystic kidney disease: urinary biomarkers as predictors. Am. J. Nephrol. 50(5), 375\u2013385 (2019).","journal-title":"Am. J. Nephrol."},{"issue":"9","key":"15681_CR26","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.34067\/KID.0000000000000525","volume":"5","author":"S Arjune","year":"2024","unstructured":"Arjune, S. et al. Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease. Kidney 5(9), 1289\u20131298 (2024).","journal-title":"Kidney"},{"issue":"6","key":"15681_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms23063317","volume":"23","author":"J Reiterov\u00e1","year":"2022","unstructured":"Reiterov\u00e1, J. & Tesa\u0159, V. Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment. Int. J. Mol. Sci. 23(6), 1 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"15681_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s10157-015-1101-7","volume":"19","author":"A Nakajima","year":"2015","unstructured":"Nakajima, A. et al. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). Clin. Exp. Nephrol. 19(6), 1199\u20131205. https:\/\/doi.org\/10.1007\/s10157-015-1101-7 (2015).","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"15681_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000438606","volume":"38","author":"CM de Lemos Barbosa","year":"2016","unstructured":"de Lemos Barbosa, C. M. et al. Regulation of CFTR expression and arginine vasopressin activity are dependent on polycystin-1 in kidney-derived cells. Cell Physiol. Biochem. 38(1), 28\u201339. https:\/\/doi.org\/10.1159\/000438606 (2016).","journal-title":"Cell Physiol. Biochem."},{"key":"15681_CR30","first-page":"10","volume":"360","author":"S Arjune","year":"2024","unstructured":"Arjune, S. et al. Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease (ADPKD). Kidney 360, 10 (2024).","journal-title":"Kidney"},{"issue":"5","key":"15681_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","volume":"56","author":"E Meijer","year":"2010","unstructured":"Meijer, E. et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am. J. Kidney Dis. 56(5), 883\u2013895 (2010).","journal-title":"Am. J. Kidney Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15681-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T03:05:43Z","timestamp":1757473543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15681-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15681"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15681-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics committee approval was obtained from the Adana City Training and Research Hospital Institutional Review Board (Approval No: 2024\u2009\u2212\u2009444). The Research has been performed in accordance with the Declaration of Helsinki. As this study is retrospective in nature, informed consent was not obtained from the subjects. The need for informed consent was deemed unnecessary according to national regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"32228"}}